Saw Palmetto: A Plain-English Research Overview

If you’ve spent more than five minutes looking into prostate supplements, you’ve come across saw palmetto. It’s in practically everything — capsules, liquids, combination formulas. It’s been used for decades, particularly in Europe where doctors have historically prescribed it alongside conventional treatments.

But here’s the question nobody on the supplement marketing page wants you to ask: what does the actual science say? Not the cherry-picked quotes. Not the “ancient wisdom” angle. The clinical trial data.

We went through it so you don’t have to. The answer, as it turns out, is more interesting (and more honest) than either the fans or the critics would have you believe.

Saw palmetto (Serenoa repens) is a small palm tree native to the southeastern United States. The supplement is extracted from its dark purple berries. It’s been used in traditional medicine for centuries, and it became a mainstream prostate supplement in Europe in the 1960s and 70s.

The primary proposed mechanism is DHT inhibition. DHT (dihydrotestosterone) is the hormone most directly linked to prostate growth. The idea is that saw palmetto partially blocks the enzyme (5-alpha reductase) that converts testosterone into DHT — essentially the same pathway targeted by prescription drugs like finasteride, but through a milder, natural mechanism.

This is where we need to be straight with you, because the picture is genuinely mixed.

The most comprehensive assessment is the 2023 Cochrane review, which analysed 27 randomised controlled trials involving over 4,600 men. Their conclusion: saw palmetto administered alone provides little to no benefit for BPH symptoms compared to placebo, in both short-term (3–6 months) and long-term (12–17 months) follow-up.

The US National Center for Complementary and Integrative Health (NCCIH) echoes this, describing saw palmetto as “probably not helpful” for urinary tract symptoms associated with prostate enlargement.

That sounds damning. But there’s important context that changes the picture.

First, the Cochrane review looked at saw palmetto alone. Most modern prostate supplements use saw palmetto as part of a combination formula — alongside ingredients like pygeum, beta-sitosterol, or marine minerals. The evidence for combination approaches is different (and in some cases better) than for single-ingredient use.

Second, many of the negative trials used lower-quality extracts or different extraction methods. Saw palmetto’s active compounds are fat-soluble, and the extraction process significantly affects what ends up in the capsule. European pharmaceutical-grade extracts (like Permixon) have shown more consistent results than generic supplements.

Third — and this is crucial — almost all studies used 320 mg per day. If a supplement contains saw palmetto as part of a small proprietary blend, it may not deliver anywhere near this dose. The dose matters enormously, and many supplements under-deliver.

This is actually saw palmetto’s strongest card. Across all 27 trials in the Cochrane review, adverse effects were mild, infrequent, and comparable to placebo. The most commonly reported side effects were minor digestive symptoms, occasional dizziness, and headache — nothing serious.

That’s a genuine advantage over prescription alternatives. Finasteride, which targets the same DHT pathway much more aggressively, carries well-documented risks including sexual side effects that can persist after stopping the drug. Saw palmetto doesn’t appear to carry these risks.

For a man in his forties experiencing mild early symptoms who wants to try something natural before going down the pharmaceutical route, this safety profile is genuinely reassuring.

Almost every credible clinical trial used 320 mg of saw palmetto extract per day, typically standardised to contain 85–95% fatty acids and sterols. Some trials split this into 160 mg twice daily; others used a single 320 mg dose. Both approaches appear equally effective.

This matters when you’re evaluating supplements. If a product contains saw palmetto as part of a “700 mg proprietary blend” with eight other ingredients, it’s mathematically impossible for saw palmetto to be at the clinically studied dose unless it makes up nearly half the entire formula. Some manufacturers do this; many don’t. Without label transparency, you simply can’t know.

If you’re serious about trying saw palmetto properly, look for either a standalone supplement at 320 mg, or a combination product that discloses individual ingredient amounts.

Saw palmetto is not a miracle ingredient. The best available evidence says it’s modest at best when used alone, and the latest Cochrane review is hard to argue with.

But it’s also not worthless. Its safety profile is excellent, it has a plausible mechanism of action, and there’s reasonable evidence that it works better in combination with other prostate-support ingredients (particularly pygeum and beta-sitosterol) than on its own. European urologists still commonly recommend it, and patient-reported satisfaction tends to be higher than the clinical scores suggest.

If you’re going to use it, use it at the right dose (320 mg/day), ideally as part of a broader approach that includes diet, exercise, and other complementary ingredients. Give it at least 8–12 weeks before judging, and manage your expectations — think “gradual improvement in daily comfort” rather than “dramatic overnight transformation.”

And if you’re curious about the ingredients that saw palmetto works best alongside, have a read of our beta-sitosterol and pygeum overviews for the full picture.